%PDF-1.4
%
22 0 obj
<>
endobj
19 0 obj
<>
endobj
71 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-24T13:24:22Z
2024-03-28T16:40:05-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T16:40:05-07:00
application/pdf
Heather
201099.omeract
uuid:faffdda3-1dd1-11b2-0a00-f508276d7200
uuid:faffdda5-1dd1-11b2-0a00-b80000000000
endstream
endobj
8 0 obj
<>
endobj
9 0 obj
<>
endobj
23 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
81 0 obj
[85 0 R]
endobj
82 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 0.2838 Tw 10 0 0 10 54 713.1616 Tm
(ographic progression, these comparisons will always be)Tj
0 Tc 0.2442 Tw 0 -1.2 TD
(flawed, and even if such an understanding existed, trial)Tj
-0.00011 Tc 0.09959 Tw T*
[(particulars \(specifics of design, dif)17.7 (ferences in conduct and)]TJ
0 Tc 0.02499 Tw T*
[(protocol populations\) make such comparisons risky)64.9 (.)]TJ
/TT1 1 Tf
-0.0002 Tc 0 Tw 0 -2.4 TD
[(SUMMAR)34.7 (Y)]TJ
/TT0 1 Tf
0 Tc 0.21941 Tw 0 -1.2 TD
(Determining what is a clinically meaningful \223no disease)Tj
-0.00011 Tc 0.0853 Tw T*
(progression\224 or \223prevention of structural damage\224 remains)Tj
0 Tc -0.01289 Tw T*
[(challenging. However)39.8 (, the availability of recent high quality)]TJ
0.04359 Tw T*
[(RCT)-275.8 (with radiographic endpoints, which show an ef)17.8 (fect on)]TJ
0.1835 Tw T*
(structural damage, provides a major opportunity to study)Tj
0.31441 Tw T*
[(several methodological issues. )17.8 (These data should allow)]TJ
-0.0022 Tw T*
(researchers to better understand the determinants of damage)Tj
0.179 Tw T*
[(in RA, further refine measurement methodology)65 (, validate)]TJ
0.19051 Tw T*
(better imaging techniques, and develop recommendations)Tj
-0.00011 Tc 0.02499 Tw T*
(for more uniform reporting of data.)Tj
/TT1 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/TT0 1 Tf
0 Tc 0.02499 Tw 8 0 0 8 61 499.1616 Tm
[(1.)-875 (Paulus HE. Heterogeneity in rheumatoid arthritis radiographic)]TJ
1.675 -1.25 Td
(trials. Issues to consider in a metaanalysis. J Rheumatol)Tj
0 Tw 0 -1.25 TD
(2000;27:249-50.)Tj
0.0249 Tw -1.675 -1.25 Td
[(2.)-875 (Food and Drug )54.8 (Administration. Guidance for industry: clinical)]TJ
1.675 -1.25 Td
(development programs for drugs, devices and biological products)Tj
T*
[(for the treatment of rheumatoid arthritis. )17.7 (W)79.8 (ashington, DC: DHHS;)]TJ
-0.00011 Tc T*
(February 1999.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (Committee for Proprietary Medicinal Products. Points to consider)]TJ
0 Tc 1.675 -1.25 Td
(on clinical investigation of slow-acting anti-rheumatic medicinal)Tj
T*
[(products in rheumatoid arthritis, European )54.8 (Agency for the)]TJ
T*
(Evaluation of Medicinal Products; January 1998.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(4.)-875.1 (Boers M, )17.7 (V)111 (erhoeven )54.8 (AC, Markusse HM, et al. Randomized)]TJ
0 Tc 1.675 -1.25 Td
(comparison of combined step-down prednisolone, methotrexate and)Tj
T*
(sulphasalazine with sulphasalazine alone in early rheumatoid)Tj
T*
(arthritis. Lancet 1997;350:309-18.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(5.)-875.1 (Bresnihan B, )54.8 (Alvara-Gracia JM, Cobby M, et al. )17.7 (T)34.8 (reatment of)]TJ
0 Tc 1.675 -1.25 Td
(rheumatoid arthritis with recombinant human IL-1 receptor)Tj
T*
[(antagonist. )54.9 (Arthritis Rheum 1998;41:2196-204.)]TJ
-0.00011 Tc 31.325 46.921 Td
[(6.)-875.1 (Sharp JT)73.9 (, Strand )17.7 (V)129.1 (, Leung H, Hurley F)79.7 (, Loew F)79.7 (,)-0.1 ( on behalf of the)]TJ
1.675 -1.25 Td
[(Leflunomide Rheumatoid )54.8 (Arthritis Investigators Group. )17.7 (T)34.8 (reatment)]TJ
T*
[(with leflunomide slows radiographic progression of RA)-220.2 (\227 results)]TJ
0 Tc T*
(from three randomized controlled trials of leflunomide in patients)Tj
T*
[(with active rheumatoid arthritis. )54.9 (Arthritis Rheum 2000;43:495-505.)]TJ
-1.675 -1.25 Td
[(7.)-875 (Finck B, Martin R, Fleischmann R, Moreland L, Schif)17.8 (f M, Bathon)]TJ
1.675 -1.25 Td
[(J. )54.9 (A)-219.8 (phase III trial of etanercept vs methotrexate in early)]TJ
-0.00011 Tc T*
[(rheumatoid arthritis [abstract]. )54.8 (Arthritis Rheum 1999;42)]TJ
0 Tw T*
[(Suppl:S1)36.8 (17.)]TJ
0 Tc 0.0249 Tw -1.675 -1.25 Td
[(8.)-875 (Lipsky P)110.8 (, St Clair )17.7 (W)91.8 (, Furst D, et al. 54 week clinical and)]TJ
-0.00011 Tc 1.675 -1.25 Td
[(radiographic results from the )54.8 (A)111 (T)-0.1 (TRACT)-257.3 (trial: )54.8 (A)-219.9 (phase III study of)]TJ
0 Tc T*
[(infliximab in patients with RA)-220.1 (despite methotrexate [abstract].)]TJ
T*
(Arthritis Rheum 1999;42:S401.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(9.)-875.1 (van der Heijde D, Boers M, Lassere M. Methodological issues in)]TJ
0 Tc 1.675 -1.25 Td
(radiographic scoring methods in rheumatoid arthritis. J Rheumatol)Tj
0 Tw T*
(1999;26:726-30.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10.)-875.1 (Molenaar ETH, Boers M, van der Heijde DMFM, et al. Imaging in)]TJ
0 Tc 2.175 -1.25 Td
(rheumatoid arthritis: Results of group discussions. J Rheumatol)Tj
0 Tw T*
(1999;26:749-51.)Tj
0.0249 Tw -2.1381 -1.25 Td
[(1)36.9 (1.)-875 (Sharp JT)74 (, Bluhm GB, Brook )54.8 (A, et al. Reproducibility of scoring)]TJ
2.1381 -1.25 Td
(radiologic abnormalities in the hands and wrists of patients with)Tj
T*
[(rheumatoid arthritis by multiple observers. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1985;28:16-24.)Tj
0.0249 Tw -2.175 -1.25 Td
[(12.)-875 (Larsen )54.8 (A, Edgren J, Harju E, Laasonen L, Reitamo )17.7 (T)74 (.)0.1 ( Interobserver)]TJ
2.175 -1.25 Td
(variation in the evaluation of radiologic changes of rheumatoid)Tj
T*
(arthritis. Scand J Rheumatol 1979;8:109-12.)Tj
-2.175 -1.25 Td
[(13.)-875 (van der Heijde D, Boonen )54.8 (A, Boers M, Kostense P)110.8 (, van der Linden)]TJ
2.175 -1.25 Td
[(S. Reading radiographs in chronological order)39.8 (, in pairs, or as single)]TJ
T*
(films has important implications for the discriminative power of)Tj
T*
(rheumatoid arthritis clinical trials. Rheumatology 1999;38:1213-20.)Tj
-2.175 -1.25 Td
[(14.)-875 (Lassere M, Boers M, van der Heijde D, et al. Smallest detectable)]TJ
2.175 -1.25 Td
[(dif)17.8 (ference in radiological progression. J Rheumatol 1999;26:731-9.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(15.)-875.1 (Boers M, )17.7 (T)34.8 (ugwell P)110.7 (, Felson DT)73.9 (, et al. )17.7 (W)79.7 (orld Health Or)17.7 (ganization)]TJ
0 Tc 2.175 -1.25 Td
[(and International League of )54.8 (Associations for Rheumatology core)]TJ
T*
(endpoints for symptom modifying antirheumatic drugs in)Tj
T*
(rheumatoid arthritis clinical trials. J Rheumatol 1994;)Tj
T*
(21 Suppl 41:86-9.)Tj
-2.175 -1.25 Td
[(16.)-875 (Leung H, Hurley F)79.8 (,)0.1 ( Strand )17.7 (V)129.1 (. Issues involved in a metaanalysis of)]TJ
2.175 -1.25 Td
[(RA)-220.1 (radiographic progression. J Rheumatol 2000;27:544-8.)]TJ
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT2 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Strand, et al: Updated r)36.9 (esear)36.9 (ch agenda)]TJ
0 Tw 61.4375 -0.0313 Td
(889)Tj
ET
0 0 0 0 scn
/GS0 gs
102.65 59.08 407.5 -10.83 re
f*
0.5 w
102.65 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
64 0 obj
<>
endobj
76 0 obj
<>
endobj
30 0 obj
<>
endobj
33 0 obj
<>
endobj
25 0 obj
<>
endobj
27 0 obj
<>
endobj
59 0 obj
<>stream
HVpT9&B K"&Y#os!+yDIY @Bte@,0v@ Qq~wPt{s?B :(M|,o`˔ ʪ5-%ЇT̮J5{ʖw@|0UU,s, ^DOWU=$
Т-({06ZLupiMt|>^z"A5/w,ۧLRT} QF^ɀ}D[zxnRZ;=4`3RY472Q*(E#؎$b{A>]:؊QK 1qc6qIĈb(kK8-ʫ֪ZӾTVAfIԃ0a&y#Fb"IE)CR.Gךk+$p|qnO#DD{n#8|VƏBn%zF>eL-?WYjZ}]v]j/a繗S'1˙{-s*uxO>;Ͻ?)WqZq#E˪`W$Q+V:J8('XBY"r<$?g&W*MyXZ6U۫3z5pmv۱v]kwM7JF3a#Y8L(IY(C%7KYͭvfOo,`vp}pay3E_fTȌŢDL3LQ)BXsԋNO+↸2Fvfg
e1GZ.kEM*w?KK'YdXuT*]
qj
^RjU?;_&j˵ڻYo.z>X/|=7s.m'usou7b?MsxSH?UV`wxET*#